Xcel Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,805
| Closed | -$641K | – | 134 |
|
|
2025
Q4 | $641K | Hold |
2,805
| – | – | 0.16% | 85 |
|
|
2025
Q3 | $649K | Sell |
2,805
-25
| -0.9% | -$5.09K | 0.17% | 87 |
|
|
2025
Q2 | $525K | Buy |
2,830
+38
| +1% | +$7.06K | 0.15% | 89 |
|
|
2025
Q1 | $585K | Sell |
2,792
-9
| -0.3% | -$1.75K | 0.18% | 83 |
|
|
2024
Q4 | $498K | Hold |
2,801
| – | – | 0.14% | 89 |
|
|
2024
Q3 | $553K | Hold |
2,801
| – | – | 0.16% | 84 |
|
|
2024
Q2 | $480K | Sell |
2,801
-55
| -2% | -$9.11K | 0.15% | 82 |
|
|
2024
Q1 | $520K | Buy |
2,856
+22
| +0.8% | +$3.79K | 0.16% | 80 |
|
|
2023
Q4 | $439K | Sell |
2,834
-250
| -8% | -$36.4K | 0.15% | 83 |
|
|
2023
Q3 | $460K | Sell |
3,084
-11,580
| -79% | -$1.7M | 0.18% | 77 |
|
|
2023
Q2 | $1.98M | Sell |
14,664
-911
| -6% | -$134K | 0.62% | 46 |
|
|
2023
Q1 | $2.48M | Buy |
15,575
+138
| +0.9% | +$21.1K | 0.87% | 31 |
|
|
2022
Q4 | $2.49M | Sell |
15,437
-109
| -0.7% | -$16.7K | 0.98% | 27 |
|
|
2022
Q3 | $2.09M | Buy |
15,546
+5
| +0% | +$717 | 0.78% | 41 |
|
|
2022
Q2 | $2.38M | Sell |
15,541
-9,576
| -38% | -$1.46M | 0.87% | 36 |
|
|
2022
Q1 | $4.07M | Sell |
25,117
-42,753
| -63% | -$6.21M | 1.12% | 25 |
|
|
2021
Q4 | $9.19M | Sell |
67,870
-139
| -0.2% | -$16.4K | 2.36% | 10 |
|
|
2021
Q3 | $7.34M | Buy |
68,009
+9,118
| +15% | +$1.04M | 2.13% | 11 |
|
|
2021
Q2 | $6.63M | Buy |
58,891
+1,785
| +3% | +$201K | 2% | 17 |
|
|
2021
Q1 | $6.18M | Buy |
57,106
+6,389
| +13% | +$683K | 2.2% | 15 |
|
|
2020
Q4 | $5.43M | Buy |
50,717
+5,631
| +12% | +$541K | 2.35% | 12 |
|
|
2020
Q3 | $3.95M | Buy |
45,086
+8,000
| +22% | +$753K | 2.03% | 15 |
|
|
2020
Q2 | $3.64M | Buy |
37,086
+2,005
| +6% | +$177K | 2.26% | 13 |
|
|
2020
Q1 | $2.67M | Buy |
35,081
+2,200
| +7% | +$187K | 2.41% | 13 |
|
|
2019
Q4 | $2.91M | Buy |
32,881
+881
| +3% | +$73.1K | 2.42% | 15 |
|
|
2019
Q3 | $2.42M | Buy |
32,000
+8,175
| +34% | +$560K | 2.24% | 15 |
|
|
2019
Q2 | $1.73M | Buy |
23,825
+12,600
| +112% | +$990K | 1.7% | 20 |
|
|
2019
Q1 | $904K | Buy |
11,225
+8,490
| +310% | +$695K | 0.93% | 33 |
|
|
2018
Q4 | $252K | Buy |
+2,735
| New | +$241K | 0.31% | 56 |
|
Other funds holding ABBV
Xcel Wealth Management's ABBV Position: Q1 2026 in Review
Xcel Wealth Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 2,805 shares — an estimated $641K sold.
Xcel Wealth Management first reported a position in ABBV in Q4 2018 and held it in 29 quarters. The position peaked at $9.19M in Q4 2021. 4,097 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Xcel Wealth Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
- Xcel Wealth Management sold 2,805 AbbVie shares in Q1 2026, an estimated $641K.
- Xcel Wealth Management first reported a position in AbbVie in Q4 2018 and held it in 29 quarters.
- Xcel Wealth Management's AbbVie position peaked at $9.19M in Q4 2021.
- 4,097 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Xcel Wealth Management's 13F filing for Q1 2026, filed 21 Apr 2026.